Compare · DYN vs NVO
DYN vs NVO
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 56.8x DYN ($3.92B).
- Over the past year, DYN is up 162.7% and NVO is down 21.8% - DYN leads by 184.5 points.
- DYN has been more active in the news (27 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 21 for DYN).
- Company
- Dyne Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $23.73+4.47%
- $50.31-2.25%
- Market cap
- $3.92B
- $222.81B
- 1M return
- +31.35%
- +15.47%
- 1Y return
- +162.70%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 27
- 5
- Recent ratings
- 21
- 25
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DYN
- Director Rhodes Jason P sold $17,858,492 worth of shares (777,451 units at $22.97) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- Director Rhodes Jason P sold $10,712,550 worth of shares (504,695 units at $21.23) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S